Teva receives eu marketing authorisation for seffalair® spiromax® and bropair® spiromax® (salmeterol xinafoate / fluticasone propionate)

Amsterdam--(business wire)--teva pharmaceuticals europe announced that it has received eu marketing authorisation for seffalair spiromax and its duplicate bropair spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. initial launches are planned in portugal, switzerland, spain and the uk. introducing seffalair spiromax and bropair spiromax the launch of
TEVA Ratings Summary
TEVA Quant Ranking